Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update


Crinetics Pharmaceuticals reported third quarter 2024 financial and provided a business update on clinical progress.

Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees.

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024


Crinetics Pharmaceuticals announced that it will report second quarter 2024 financial results on Tuesday, November 12, after the close of the U.S. financial markets.

Crinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new non-executive employees.

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock


Crinetics announces the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share